Bariatric Procedures and Changes in Incretins and Gastric Emptying (BIG)
Morbid Obesity
About this trial
This is an interventional diagnostic trial for Morbid Obesity
Eligibility Criteria
Inclusion Criteria:
- Patients must be able to adhere to the study visit schedule and protocol requirements
- Patients must be able to give informed consent and the consent must be obtained prior to any study procedures
- Patients who had a follow-up period up till 2 years after bariatric surgery without any complications or
- Patients are eligible for DJBL implantation
Exclusion Criteria:
- Binge-eating or associated eating disorder
- Active drug or alcohol addiction
- Pregnancy or giving breast feeding
- Gluten allergy
- Inability to stop medication that affects the motility of the upper GI tract (anti-cholinergic drugs, prokinetics, theophylline, calcium blocking agents, opioids)
- Endocrine disease influencing gastric emptying (diabetes mellitus, hyper- or hypothyroidism). Type 2 diabetes mellitus is not an exclusion criterium for patients receiving the DJBL.
Sites / Locations
- Rijnstate hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Other
Other
Other
Other
Other
Good responder RYGB
Bad responder RYGB
Good responder SG
Bad responder SG
Duodenal-jejunal bypass liner
Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL